Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 17/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15725966 | 0.96 | FGFR3 (0.69) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16388955 | 0.95 | FGFR3 (0.68) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15244519 | 0.94 | FGFR3 (0.63) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15728675 | 0.91 | FGFR3 (0.62) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725964 | 0.91 | FGFR3 (0.64) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15728678 | 0.90 | FGFR3 (0.74) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15725972 | 0.88 | FGFR3 (0.61) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15244391 | 0.88 | FGFR3 (0.59) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL15244340 | 0.86 | FGFR3 (0.81) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL18132654 | 0.86 | FGFR3 (0.69) | FGFR3KCNH2FGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2821402-B1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2019-08-21 | — | — | EP | disclosed |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| EP-2821402-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | FGFR3 901/4885KCNH2 1496/4885FGFR1 580/4885 |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | FGFR3 1/4885KCNH2 3097/4885FGFR1 2/4885 |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | FGFR3 1/4885KCNH2 2907/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.